Skip to main content
CDC Website

MMWR: Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000

This report discusses two cases of latent TB infection in which patients developed severe or fatal hepatitis associated with rifampin-pyrazinamide (RIF-PZA) treatment.

Audiences:
Health Professionals
Author:
Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR
Focus Area:
TB
Subjects:
Treatment- Adverse Reactions
Treatment - Latent TB infection (Inactive TB)
TB Treatment
Treatment- Medication Information
Publication Date:
2001
Format:
Report
3 p.: b&w; refs.
Links:
http://www.cdc.gov/mmwr/PDF/wk/mm5015.pdf
Links:
Last Updated Date:
Publication ID:
31545